Tag Archives: HEA

PR Newswire

Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020

Leave a comment

Digital POCT platforms will enable diagnostic testing beyond the clinic, transforming how assay results are gathered and analyzed, finds Frost & Sullivan

SANTA CLARA, California, Oct. 2, 2020 — Frost & Sullivan’s recent analysis, Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024, finds that the outbreak of the COVID-19 pandemic has transformed the infectious disease point-of-care testing (POCT) market. The emergence of cost-effective lab-on-a-chip and smartphone-based POCTs, alongside increasing reliance on less-invasive testing methodologies, will propel the POCT market. Globally, the infectious disease POCT market is estimated to witness more than a three-fold growth, reaching $26.4 billion by 2024 from $7.9 billion in 2019, up at a compound annual growth rate (CAGR) of 27.3%.

Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020
Smartphone-based Solutions Boost the Global Infectious Disease Point-of-Care Testing Market at an Explosive CAGR of 70.2% in 2020

For further information on this analysis, please visit: http://frost.ly/4l1.

"The POCT instrument selection process should involve close collaboration with supply and clinical engineering departments to incorporate their input and feedback," said Amartya Bose, Healthcare Industry Analyst at Frost & Sullivan. "This is a key consideration when the POCT committee reviews all options and makes an informed decision. Hospitals/labs/pharmacies should select regional vendors for device procurement and services. This will reduce the procurement lead time and ensure devices are managed for quality assurance, timely calibrations, and interpretation of results."

Nitin Naik, Life Sciences Vice President at Frost & Sullivan, added: "The application of artificial intelligence (AI) and machine learning (ML) is a key growth opportunity for manufacturers to enhance their product portfolios. By leveraging these platforms, POCT assay menus can be expanded for different patient groups by simply iterating the product development cycle. U.S. healthcare providers are also leveraging digital POCT along with virtual assistants to screen and triage asymptomatic patients."

To capitalize on growth opportunities in the current and post-COVID-19 situation, POCT market participants should focus on the following solutions:

  • Multiplexed POCT: Integrate sample preparation and analysis within one device to offer more advantages in a competitive environment.
  • COVID-19 POCT: Develop accurate serology tests and mHealth-based diagnostics, as they will play a critical role in determining the disease’s full scope, combating the pandemic.
  • Digital POCT: Adopt cloud technologies as an integral part of device development to reduce the footprint and cost of POCT devices.
  • Millennials and sexually transmitted infections (STIs): Produce HIV/syphilis dual tests as evidence suggests a two- to five-fold increased risk of acquiring HIV if exposed to it when syphilis is present.

Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024 is the latest addition to Frost & Sullivan’s Healthcare research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024
K4C6

Contact:
Mariana Fernandez
Corporate Communications
P: +1 210 348 10 12
E: Mariana.Fernandez@frost.com
http://ww2.frost.com

Photo – https://techent.tv/wp-content/uploads/2020/10/smartphone-based-solutions-boost-the-global-infectious-disease-point-of-care-testing-market-at-an-explosive-cagr-of-70-2-in-2020.jpg

 

Related Links :

Frost New Home page v2

PR Newswire

Turning AI onto itself: AI algorithm detects when medical images will be difficult for radiologists or AI to make an effective diagnosis

Leave a comment

SAN FRANCISCO, Sept. 30, 2020 — A new AI algorithm can identify when medical images are likely to be difficult for either a radiologist or AI to make an effective diagnosis. The algorithm can potentially be used to triage medical scans and highlight cases that warrant further in-depth clinical evaluation or additional tests to support a definitive clinical diagnosis.

Radiologist diagnosing x-ray scan
Radiologist diagnosing x-ray scan

The algorithm, called UDC by AI healthcare company Presagen, was originally designed to automatically detect errors in medical data, particularly data that cannot be reliably verified by experts.

When applied to images of x-rays to detect pneumonia, errors by radiologists were rare when the x-ray images had clear features. However, UDC found the diagnosis (or label) for several x-ray images to be neither correct nor an error. Verification of these images by an independent radiologist also agreed that they were indeed difficult images to diagnose, with their independent assessment often disagreeing with the original diagnosis provided in the public dataset. Similarly, AI that was trained to diagnose pneumonia also found the assessment difficult for these images.

Removal of poor-quality (difficult) images identified by UDC from the training dataset improved AI accuracy for diagnosing pneumonia in x-rays images by over 10% as measured on a hold out blind test set, and the AI was shown to be more scalable (generalizable). The accuracy also exceeded benchmarks set by the current literature for that public dataset.

The AI Scientist that led the project, Dr Milad Dakka, said "Our results suggest these poor-quality images are uninformative, counter-productive or confusing when used in training AI. The ability to identify when new images are poor-quality is important to prevent an inaccurate AI clinical assessment, but also to alert the radiologist when the scan is likely to be difficult to diagnose or when a new scan should be taken."

Presagen Co-Founder and Chief Strategy Officer, Dr Don Perugini said "Many AI practitioners believe that AI performance and scalability can be solved with more data. This is not true, and we call it the AI data fallacy. Even 1% poor-quality data can impact the performance of the AI. Building accurate and scalable AI is about using the right data."

Presagen has recently developed a range of patent-pending AI technologies that drive a fundamental paradigm shift in developing commercially scalable AI products for real-world problems, which apply beyond healthcare and to AI more generally.

Dr Michelle Perugini said "We are excited to present to the world the suite of technologies, which we believe advance the field of AI. These technologies will allow Presagen to build scalable ‘out of the box’ AI products that are more commercially viable and technically superior, and thus market dominating. This is vital in Presagen’s journey to become world-leaders in AI Enhanced Healthcare and a dominant player in the AI-in-Femtech market globally. More importantly, we see it as an opportunity to change, lead, and dominate the AI industry."

 

Related Links :

https://www.presagen.com/

PR Newswire

Pangyo Techno Valley’s 100 Bio & Medical Special – MIK HOT SPOT Online Exhibition to open on September 4

Leave a comment

New attempt to promote Korean companies to domestic and foreign markets in post-coronavirus era.

SEOUL, South Korea, Sept. 25, 2020 — AVING NEWS’ Korea’s only convention media and online exhibition center by itself, began this project to help Korean companies to enter the domestic and foreign markets through MIK HOT SPOT (Made in Korea Online Exhibition) on its way to become the global online hot spot.

The online exhibition consists of opening the MIK ONLINE HOT SPOT exhibition, business introduction video for buyers and investors, domestic and global promotion, target promotion for MIK HOT SPOT network, and post-management after contacting the buyers and investors, open for 365 days a year.

The five companies that participated in the MIK HOT SPOT_Pangyo Techno Valley 100 Bio & Medical Special are as follows:

  • M2S
  • Rootee Health
  • Exosystems
  • Genome & Company
  • AllLive Healthcare

– M2S

M2S, a digital healthcare specialist, is a startup company that develops and operates eye-related care services and platforms, including its VR ophthalmic testing device VROR. M2S has received spotlight in the global market when VROR, the ophthalmic testing device using virtual reality (VR), was approved by the US FDA in December of last year. The company has 12 domestic and foreign patents related to ophthalmic examination, including the domestic original patents for ophthalmic examination with VR and eye tracking technology. To enter the global market with the ability to create innovative VR AR-based digital contents, M2S is planning to launch Eye.Dr VR, a digital healthcare solution for eye health management in September.

– Rootee Health

ELI Solution provided by Rootee Health is an eye disease test solution that can be easily used by the general public. The feature of this product lies in the eye examination automation technology that automates the process of obtaining good images with AI technology while being portable. "If you just place your face like a VR, the eye exam is done within 10 seconds, and you can finish the eye exam for both eyes within 30 seconds. It is the first portable automatic photographic eye exam device. Because it is portable, it has a big advantage over conventional fixed fundus camera," CEO Guk Gyeong-min said.

– Exo Systems

Lee Hu-man, the CEO of Exosystems, has developed ExoRehab that helps rehabilitate the musculoskeletal system as he founded the company. CEO Lee said, "The most core value of ExoRehab is to train and restore the muscles that make up the musculoskeletal system. The biosignal wearable device analyzes the biosignals of the wearer and provides an exercise program suitable for them in software form. For those who have difficulty in exercising, it provides medical electrical stimulation to help restore muscle."

– Genome & Company

Genome & Company is a bio-venture company established in 2015, developing next-generation innovative new drugs in the field of immune anticancer drugs such as microbiome, new target immune checkpoint inhibitors, and fusion proteins to overcome unmet medical demands of cancer patients. The company is the first Korean microbiome research and development company to collaborate in a clinical trial of concomitant use and supply contract of Merck and Pfizer’s immune anticancer drug Avelumab (product name: Bavencio) and its own immune anticancer microbiome treatment (GEN-001) in December last year. In April of this year, the US Food and Drug Administration (FDA) approved the clinical trial plan (IND), and the clinical trial of concomitant use is in progress. Along with this. in December last year, it concluded an MOU with LG Chem for the exclusive development and commercialization rights for GEN-001 in Korea and the East Asian region.

– AllLive Healthcare

AllLiveC is a platform operated by AllLive Healthcare, Korea’s no. 1 clinical trial support service provider. It is providing the clinical trial online/offline integrated brokerage service that connects applicants who want to participate and the clinical trial centers. Clinical trial is the most important process in the development of new drugs, and a huge amount of time and money is spent. AllLive Healthcare has the goal to innovate these clinical trials with IT technology, and as the first step, it has made the platform that provides the service of recruiting and managing the subjects for clinical trials. By using the IT technology, the recruitment of clinical trial subjects that had been conducted manually is done by AllLiveC, the clinical online/offline clinical trial brokerage service’ It is announcing the clinical trials by online media.

Pangyo Techno Valley, which participated in MIK HOT SPOT (Made in Korea Online Exhibition), is a business platform where companies with innovative products and technologies are gathered. About 1,300 companies in IT, CT, and BT sectors are based here. Innovative companies with global capabilities like Kakao, NHN Entertainment, AhnLab, Krafton, NCSOFT, Nexon, and Hancom, and advanced technology research institutes like Advanced Institute of Convergence Technology, KAIST, ETRI, and KETI are working together.

The global news network AVING News has begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small and medium-sized companies enter the market and attract investment 365 days a year. AVING News has been running online exhibitions since 2005 and had 975 online exhibitions so far. Its YouTube online exhibition has placed itself as Korea’s largest online exhibition hall that opens with 19,000 videos (booths) with more than 800,000 visits per month which means more than 10 million visits per year.

The MIK HOT SPOT online exhibition is scheduled to be held regularly according to the field, target market, and participating institutions, and it will be presented as a new type of online business by transforming the know-hows and values of the participating companies according to the trend. Companies that want to participate can apply and apply through the marketing support projects from supporting institutions in the local governments. Refer to the institutions for more information.

– Go to MIK Hot Spot (Made in Korea Online Exhibition) special page
http://www.madeinkorea.tv/

PR Newswire

Ultromics Lauded by Frost & Sullivan for Pioneering AI-based Cardiovascular Suite, EchoGo

Leave a comment

The SaaS suite helps physicians automate key measurements and predict the occurrence of CAD, enabling clinicians to proactively recommend preventive actions that improve patient outcomes

LONDON, Sept. 25, 2020 — Based on its recent analysis of the global AI-based echocardiography market, Frost & Sullivan recognizes Ultromics with the 2020 Global New Product Innovation Award for enhancing diagnostic quality in cardiac care units with its AI suite, EchoGo. The FDA and CE-cleared solutions (respectively EchoGo Core and EchoGo Pro) not only automate measurements for heart functions but also empower physicians to predict the occurrence of coronary artery disease (CAD). With a cloud-based Software-as-a-Service (SaaS) format, they enable quick deployment, minimal training, and hassle-free upgrades.

2020 Global AI-based Echocardiography New Product Innovation Award
2020 Global AI-based Echocardiography New Product Innovation Award

Click here to download the full report: https://ultromics.com/best-practices-award/

"Ultromics’ EchoGo Core performs cardiac measurements, including ejection fraction (EF), global longitudinal strain (GLS), left ventricular (LV) volume, and myocardial strain reporting. By automating these measurements, Ultromics eases one of the most tedious steps in cardiovascular conditions’ diagnosis, thus saving time and removing inter-operator variability," said Parth Shah Research Analyst. "Meanwhile, EchoGo Pro serves as a clinical decision support tool for physicians by assessing the risk profiles of patients. As an industry-first solution within cardiac echocardiography, it enables early detection and prevention of CAD supported by evidence at the point of care."

Furthermore, being a cloud-based solution, it can be delivered as a SaaS model, which allows deployments to be completed faster than with traditional PACS software integrations. The SaaS model also does away with the need for future upgrades, patches, and associated fees. The solution is designed to be intuitive, minimizing the need for substantial user training required by other solutions. Once usage begins, it employs a zero-click, off-the-cart usage approach, eliminating the need for users to manually upload or cross-launch scans.

Being a vendor-neutral solution, Ultromics can target any provider, regardless of the echocardiography equipment they use, across regions. While the EchoGo solutions are currently available in the western markets, Ultromics will target the Asia-Pacific market in the future. Its adoption in developed markets received a major boost in 2020 when the Strain procedure obtained a CPT code that allows physicians to report and bill myocardial strain diagnosis. It is also one of the very few AI solutions in the imaging space to qualify for reimbursement.

"EchoGo’s pricing structure delivers significant return on investment with no upfront costs. While competitors offer comparable price points, their need for additional software upgrades and associated installation costs and efforts make them more expensive in the long term. Ultromics adopts a pay-per-use pricing model but can also offer a subscription model depending on the volume of procedures being conducted," noted Shah. "EchoGo automates the entire process, allowing physicians to save on costs while having zero user interactions to obtain results. Overall, Ultromics’ price-value proposition helps it capture a larger share of the market and positions it for continued growth globally."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Harley Gadomski
P: 12104778469
E: harley.gadomski@frost.com

About Ultromics

Ultromics is a global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions empowering physicians to make fast, accurate decisions when diagnosing cardiovascular disease. EchoGo, the world’s first autonomous echocardiography service provides cloud-based artificial intelligence services to support cardiac imaging diagnosis without any variability or need to touch software. Our technology was born at the University of Oxford and built in partnership with the NHS, and has since raised over £20 million to help improve patient care, and bring diagnostic quality and resource savings to hospitals. Cardiovascular disease is the leading cause of mortality, with an estimated 17 million deaths each year. www.ultromics.com

CONTACT:       
Kyle Souligne
Director of Marketing – Ultromics
Kyle.Souligne@Ultromics.com 

Photo – https://techent.tv/wp-content/uploads/2020/09/ultromics-lauded-by-frost-sullivan-for-pioneering-ai-based-cardiovascular-suite-echogo.jpg

Related Links :

Frost New Home page v2

PR Newswire

Qatar Foundation’s WISE Announces Special E-Book

Leave a comment

Education Disrupted, Education Reimagined – Responses from education’s frontline during the COVID-19 pandemic and beyond

DOHA, Qatar, Sept. 22, 2020 — WISE, a Qatar Foundation global education think-tank, in partnership with Salzburg Global Seminar, and Diplomatic Courier, is pleased to announce the official release of a special E-Book titled: Education Disrupted, Education Reimagined – Responses from education’s frontline during the COVID-19 pandemic and beyond.

WISE E-Book Cover
WISE E-Book Cover

The special edition E-Book was produced in real time, as WISE, in partnership with Salzburg Global Seminar, convened key stakeholders and education leaders from over 98 countries in a three-part series of global conferences aimed at bringing the global education community together. The result was a contemporary historical record of how schools, NGOs, governments, and international organizations responded to school closures during the crisis and how they are attempting to use this crisis as a springboard to reimagine – and even transform – education in their communities and countries.

The E-Book offers an opportunity to a global audience to make sense of what happened, but it also offers a breeding ground of ideas from some of the world’s top education thinkers.

"It is our hope that this publication will provide the education community with a reference point from the crisis from which future research, policy, and innovation can grow," said Dr. Asmaa Al-Fadala, editor of the publication and Director of Research and Content Development at WISE.

Contributors include:

  • Her Excellency Sheikha Hind bint Hamad Al-Thani
  • The Right Honorable Gordon Brown
  • Marc A. Brackett
  • Andreas Schleicher
  • Stefania Giannini
  • Manos Antoninis
  • Olli-Pekka Heinonen

To download the Digital Edition of the book, please click here.

Email media@wise.org.qa to receive more information or to request experts for media appearances.

WISE is also hosting a virtual session during the Global Goals Week, on September 29 at 3:30PM (GMT+3) to launch the e-book. Six of the e-book’s authors will discuss the future of education in a post-COVID-19 world during this panel session.

You can register to the session here.

About WISE: WISE is an international, multi-sectoral platform for creative thinking, debate and purposeful action. WISE has established itself as a global reference in new approaches to education. Through both the biennial Summit and a range of ongoing programs WISE is promoting innovation and building the future of education through collaboration. 

Photo – https://techent.tv/wp-content/uploads/2020/09/qatar-foundations-wise-announces-special-e-book.jpg
Logo – https://techent.tv/wp-content/uploads/2020/09/qatar-foundations-wise-announces-special-e-book-2.jpg

Press Contact:
Lina Lahlou
media@wise.org.qa

Related Links :

Home page

PR Newswire

Amazfit Band 5 Launched with Blood Oxygen Saturation, 15-day Battery Life[1] at 44.9USD[2] on Sept. 21st, and Amazon Alexa Built-in[3] Coming Soon

Leave a comment

Can A Band Be Smarter? Check this All-round Band with Varied Health Management and Alexa Built-in.

SHENZHEN, China, Sept. 21, 2020 — Amazfit Band 5, a smart wrist band, launched as the latest offering of Huami to the excellence of Amazfit wearable lineup. Amazfit Band 5 features the very most of the functions what you have as a sports gym band, but also a thorough health management assistant and a smarter wrist band with frequent-used interactions thanks to the upcoming powerful built-in Alexa functions. With an affordable price, Amazfit Band 5 aims to help the public, aged from 18-50 years old or even beyond, to Stay Active and Stay Young in a challenging world nowadays, especially the health conscious and light sportive who seek for better budget.

A Band of Thorough and Science-based Personal Health Management[4]

The category of wearable band normally was considered as basic device at low price. But Amazfit Band 5 makes the "band" category upgraded, especially the personal health management.

  • The precise BioTracker™ 2: Although Amazfit is not a medical device but it shipped with the newest generation PPG optical sensor, Huami BioTracker™ 2nd, providing high-precision 24/7 continuous heart rate measurement with resting heart rate, heart rate zones and high heart rate alert which is the most versatile and precise biosensor ever developed by Huami.
  • The advanced OxygenBeatsTM enables Amazfit Band 5 for Blood Oxygen Saturation measurement, powered by Huami self-developed oxygen data AI engine. Compared with the results of professional oxygen analyzers, the average error of OxygenBeatsTM  is only 1.67%[5] reflecting accuracy superior to that of most wearable wrist devices for blood oxygen detection. The OxygenBeatsTM is applied to the follow-up visits with recovered COVID-19 patients in China.
  • The science-backed PAI™ is the Personal Activity Intelligence Assessment System based on the PaiHealth research[6] from Norway. By a simple activity tracking metric, you can interpret your daily heart rate data into a single and personal score to know how much activity is needed to stay healthy. Backed by science research, that maintaining over 100 PAI is associated with adding up to 5 years[7] to your life and reducing the risk of cardiovascular disease mortality by an average of 25%[8]. Try Amazfit Band 5, you will refresh your understanding of what a heart gym is.
  • Sleep Quality Monitoring can measure your total sleep, light sleep, deep sleep and rapid eye movement (REM) to understand your sleep patterns. Amazfit Band 5 take care of your sleep even during your nap time that of more than 20 minutes in the daytime.
  • Menstrual Period Tracking help the female keep track of the menstrual periods and ovulation periods, and alert ladies before it arrives.
  • Stress Monitoring will calculate your stress level through your heart rate variability with 4 levels including relaxed, normal, medium and high.
  • Breathing Exercise will guide you to a deep breathing session helping you release the stress.
Amazfit Band 5 Launched with Blood Oxygen Saturation, 15-day Battery Life at 44.9USD on Sept. 21st, and Amazon Alexa Built-in
Amazfit Band 5 Launched with Blood Oxygen Saturation, 15-day Battery Life at 44.9USD on Sept. 21st, and Amazon Alexa Built-in

An All-around Band that Everyone Deserves as a Gym and Health Wrist Band

Amazfit Band 5 is currently such an all-round band in the market that brings competitive hardware, software and functions among the wearable bands of the similar price. It ships a 1.1" AMOLED color display with a resolution of 126×294. Even at such a nice price, the screen comes with 2.5D tempered glass and anti-fingerprint coating.

It is light and only weighs 12g without strap. By the Bluetooth 5.0 and power-saving technologies, the 125 mAh battery can keep Amazfit Band 5 working up to 15 days in a typical usage scenario, 25 days in power-saving scenario and standby around 3 months.[9]

Amazfit Band 5 comes with a skin friendly TPU strap of three colors and supports 11 sports modes including swimming thanks to the 5ATM[10] waterproof. It offers a large selection of more than 45 watch faces to download from the App, 2 watch faces support editable widgets so users can personalize them, and even add their own personal picture in the background.

Amazfit Band 5 Can be the Smarter One of the Bands

Can a wrist band be smarter?

The answer is positive. Amazfit Band 5 can make life easier and more fun with Amazon Alexa[11]. With Alexa, you can ask questions, search information, get translations, create shopping lists, set alarms and timers, reminders, check the weather, check notifications, make smart home commands and more. You can talk to Amazfit Band 5, and it responds to users’ voice commands on screen with text responses. For example, just say,

  • "Alexa set a pasta timer. "
  • "Alexa add eggs to my shopping lists."
  • "Alexa turn on the living room lights."
  • "Alexa who is Barack Obama?"

Alexa lives in the cloud, so it’s always getting smarter, adding new capabilities that are delivered to your device automatically. Using Alexa on Amazfit Band 5 is simple and hands-free – just ask, and Alexa will respond instantly. 

IMPORTANT:

  • Amazfit Band 5 is first on sale from September 21st via Amazon in US market. Other market will follow from October.
  • Built-in Alexa capabilities will be enbaled by free OTA updates in the available markets.
  • Download HQ Images of Amazfit Band 5 here, https://bit.ly/3hbyk6M 

About Amazfit

Established in September 2015, Amazfit is a private brand owned by Huami Technology (NYSE: HMI), offering seven series of smartwatch and bracelets products including the Stratos series, Basic series, Flagship series, Health series, Fashion series, Outdoor series, and X series. Amazfit also provide other smart hardware related to sports and health, including TWS sports earbuds, smart treadmills, smart body fat scales and sports gear. With outstanding design and craftsmanship, Amazfit smart watch products have won many prizes, such as the German iF Industrial Design Award and the Red Dot Design Award. Currently, Amazfit products hit the markets of more than 70 countries and regions, including the United States, Germany, and Japan. According to an IDC global wearable device market tracking report, in the first half of 2020, Amazfit watches claimed the largest share of the adult watch market in Italy, Spain, India and other regions, and were also among the top products in regions such as China, Germany, France, Russia, and Brazil.

Find more details about us, https://en.amazfit.com/about.html

Huami Technology, operating since 2013, is a cloud-based healthcare service provider offering the world’s leading smart wearable technologies. In February 2018, Huami Technology was listed on the New York Stock Exchange (NYSE) (stock code: HMI).

Media Contact
press@huami.com 

[1] Battery life test under lab conditions, may vary by usage and conditions
[2] Retail price may vary on markets.
[3] The Built-in Alexa of Amazfit Band 5 will be available by OTA upgrade soon if the market is Alexa available. When available, notifications will be appeared via the Zepp APP (formly known as Amazfit APP) and device. The OTA push time may vary by markets.
[4] This product isn’t a medical device. All data and measurements aren’t intended for medical diagnosis or medical monitoring.
[5] According to Huami’s AI Innovation Conference Keynote, June, 2020
[6] The Science of PAI. Researchers used the HUNT Study data to validate PAI. The HUNT Study is one of the largest health studies ever and was performed by the Nobel Prize-winning Faculty of Medicine at the Norwegian University of Science and Technology. It contains a unique database of the personal and family medical histories of more than 45,000 people over 25 years. https://www.paihealth.com/science-of-pai/default.htm
[7] By applying the PAI algorithm to the HUNT data, researchers found that when individuals consistently exercised at intensities equal to maintaining 100 PAI, it was associated with a reduced risk of cardiovascular disease mortality by an average of 25% and a reduced risk of mortality from other lifestyle-related diseases for men and women of all ages. They also saw that maintaining 100 PAI was associated with an increased life expectancy by an average of 5 years. Quoted from https://www.paihealth.com/science-of-pai/default.htm original link https://cdn.flipsnack.com/widget/v2/widget.html?hash=fd1pf7owi, also see <Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity> https://www.amjmed.com/article/S0002-9343(16)31069-5/abstract
[8] See above footnotes
[9] Battery life test under lab conditions, may vary by usage and conditions
[10] The device passed the test of water resistance level of 5 ATM conducted by third-party institutions.
[11] Will come by OTA update. US market will come first. Other markets will follow if Alexa is avaible.

Photo – https://photos.prnasia.com/prnh/20200917/2919079-1?lang=0

Related Links :

http://en.amazfit.com/about.html

PR Newswire

ReTo Eco-Solutions Signs Cooperation Agreement to Build Large Scale Industrial Park and Elderly Wellness Town in Yangbi County

Leave a comment

BEIJING, Sept. 16, 2020 — ReTo Eco-Solutions, Inc. (the "Company," "we" or "ReTo") (NASDAQ: RETO), a one-stop, total technology solutions provider for the healthy improvement of ecological environments, today announced that it signed a cooperation agreement with the People’s Government of Yangbi Yi Autonomous County.  Under the agreement, in Yangbi County the Company will be responsible for the planning, design and construction of an industrial park and elderly wellness town, which development is promoted by the government.

The large scale project covers 125 hectares, with 58 hectares designated for an ecologically-friendly industrial park and 67 hectares designated for an elderly wellness town providing healthcare, and serving as a destination for travel and vacations.  The geological survey for the project site is already underway, with preliminary work expected to take about four months, allowing for construction to commence in the first quarter of 2021.

Yangbi County is fast becoming an alternative eco-tourism center given its proximity to the historic, but over developed Dali City. Yangbi County is an hour’s drive from the Dali Airport and is close to Cangshan, another famous Chinese tourist attraction.  The natural environment and rich natural resources provide beneficial conditions for the development and operation of an elderly wellness town.  The area also benefits from active government support and attractive financial incentive programs designed to encourage development, eco-tourism and environmental protections.

Mr. Li Hengfang, ReTo’s Chairman and Chief Executive Officer, commented, "We greatly appreciate and value the confidence, support and partnership of the Yangbi government.  This important agreement further extends our relationship, as it builds on the previous projects we have signed in Yangbi County, for solid waste treatment, and ecological restoration, among others.  Our model of ecological restoration and industrial integration is unique and we believe offers compelling long-term benefits to the communities we operate in.  Our sustainable projects are scalable by design and help our partners achieve a better balance of social capital and environmental protection polices to the benefit of the broader society."

About ReTo Eco-Solutions, Inc. (NASDAQ: RETO)

Founded in 1999, ReTo (NASDAQ: RETO) is a leader in ecological innovation, with sustainable environmental priorities and seeks to empower communities through its proprietary technologies, systems and solutions, which have been used to bring clean water and fertile soil to villages and cities worldwide. The Company is founded on its strategy of Technology Improves Ecology and is a full spectrum provider of products and services, ranging from the production of environmentally-friendly construction materials, environmental protection equipment and manufacturing equipment used to produce environmentally-friendly construction materials, to project consulting, design and installation for the health and improvement of ecological environments,  such as ecological soil restoration, through solid waste treatment.  For more information, please visit: http://en.retoeco.com

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.  Specifically, the Company’s statements regarding: 1) its ability to assist in environmental protection; and 2) its ability to complete the construction of the industrial park and elderly wellness town are forward-looking statements.  Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of construction and ecological solutions in China and internationally; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and internationally and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

 

Related Links :

http://en.retoeco.com

PR Newswire

Booming Demand for Innodisk’s CAN Bus Solutions Amid Pandemic and Autonomous Vehicle Trend

Leave a comment

Innodisk’s expanding CAN bus product line sees skyrocketing demand

TAIPEI, Sept. 11, 2020 — Innodisk’s CAN bus expansion modules are taking the world by storm. Unprecedented demand for autonomous vehicle technology amid the ongoing COVID-19 pandemic and continued growth of industrial automation and smart healthcare mean that Innodisk’s industry-leading CAN bus solutions are in high demand.

Sales Doubled in 2020

Innodisk’s long-standing expertise in industrial markets and its commitment to CAN bus innovation have made it a key supplier to innovators – large and small – in the autonomous vehicle, automation, and medical markets. As a result, Innodisk’s CAN bus product line sales nearly doubled in the first half of 2020, with unit sales in that period already surpassing full-year sales in 2019.

Innovations Tailored for Autonomous Vehicles

Modern autonomous vehicle systems depend on many sensors in lidar, radar, and camera systems for autonomous navigation in diverse roadside environments. This large number of sensors requires that the vehicle controller system is equipped with enough CAN bus ports.

Innodisk designed its new four-port M.2 to CAN bus expansion module (EGPC-B4S1) to address this demand. The expansion module provides vehicle controller systems with four additional CAN bus ports per card, satisfying autonomous vehicles’ growing demands for CAN bus ports and giving manufacturers new opportunities to innovate.

Industrial-Grade CAN Bus Expansion Designed for the Future

The new Innodisk EGPC-B4S1 CAN bus module launches in the third quarter of 2020 and joins the two-port M.2 and mPCIe to CAN bus expansion modules in Innodisk’s growing CAN bus lineup. Higher-level protocol support for SAE J1939 and CANopen launches for EGPC-B4S1 in Q4 2020 and is already fully supported in Innodisk’s existing CAN bus modules.

Innodisk’s CAN bus expansion modules are designed for industrial applications, featuring support for extreme temperatures (-40 degree Celsius to 85 degree Celsius), electrostatic discharge protection (air: 15 kV, contact: 8 kV), as well as 2 kV HiPot protection – bringing CAN bus innovation to any industrial application.

About Innodisk

Innodisk is a service-driven provider of flash memory, DRAM modules, and embedded peripheral products for industrial and enterprise applications. With satisfied customers across a range of demanding industries, we have set ourselves apart with a commitment to exceptional products and service.

For more information about Innodisk, please visit https://www.innodisk.com

Logo – https://photos.prnasia.com/prnh/20200313/2748001-1LOGO?lang=0

PR Newswire

Pharmalutions And Movilitas.Cloud Deliver Serialization Solutions for the Asia-Pacific Region

Leave a comment

Partnership Provides Greater Access to End-To-End Serialization and Track & Trace Solutions

COLUMBIA, Md., Sept. 11, 2020 — Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while improving operational efficiencies to deliver safer pharmaceuticals to patients.

Several countries in the Asia-Pacific region, such as Indonesia, Thailand and Malaysia, have already established or announced the introduction of serialization regulations for medicines. As track & trace regulations further spread and evolve, this partnership ensures that safer products reach consumers. It makes compliance for life science manufacturers simple, offering a holistic solution connecting the serialization equipment on the shop floor with an out-of-box level 3-5 track & trace solution that is configurable for the specific needs of different participants in the supply chain.

"We have been involved in product-serialization and aggregation since 2004," said Tilman Joerss, Founder and Director of Pharmalutions. "This is 15 years ahead of the EU-FMD deadline [February 2019], and it provided us with a valuable long-term perspective of the regulatory landscape and its evolutionary nature. Today, this broad experience serves our customers well in dealing with much faster approaching deadlines while safeguarding their long-run investments into product-traceability. Rapid deployment of future-proof technology. That is the key and why Movilitas.Cloud is a perfect match."

To learn more about the Movilitas.Cloud solution, please visit: https://www.movilitas.com/solutions/movilitas-cloud/

About Pharmalutions Pte LTD

Founded in 2010 in Singapore, Pharmalutions Pte Ltd is a specialist for multi-regulatory Track & Trace (T&T) based on product-serialization, with a distinct focus on pharmaceutical compliance. Pharmalutions evolved from Regional System Integrator to become a private-label in 2019. Today, Pharmalutions is an officially recognised GS1 Singapore Solution-Partner (SSP). A 10-years-history powers Pharmalutions with a unique long-term perspective on global T&T. Its deeply rooted network stretches from Europe to Asia-Pacific, across industries.

For more information, visit Pharmalutions.net or LinkedIn

About Movilitas

Movilitas is a technology leader delivering the next generation of solutions and consulting services across multiple industries to advance smart supply chain ecosystems. We are recognized as a trusted SAP partner for digital supply chain transformation. We help businesses realize new growth opportunities, adapt to today’s on-demand economy and maintain compliance. Through services, such as Movilitas.Cloud, or extensions and accelerators for SAP solutions, our clients unlock data to realize greater efficiencies and new revenue streams. For more information, visit movilitas.com, or LinkedIn, Twitter or Xing.

CONTACT: marketing@movilitas.com

Logo – https://techent.tv/wp-content/uploads/2020/09/pharmalutions-and-movilitas-cloud-deliver-serialization-solutions-for-the-asia-pacific-region.jpg

Related Links :

http://www.movilitas.com

PR Newswire

Cyient Enters into a Manufacturing Collaboration with Agappe to Bring World-Class Diagnostic Capabilities to Rural India

Leave a comment

HYDERABAD, India, Sept. 10, 2020 — Cyient, a global engineering and digital technology solutions company, today announced that it has entered into a manufacturing partnership with Agappe to bring to market Count X. The Mispa Count X is an indigenously designed and developed three-part hematology analyzer by Agappe, that will make India self-reliant in hematology and enable the setup of well-equipped labs in remote and rural locations across India. Cyient will manufacture certain key components of Mispa Count X at its ISO 13485-certified, state-of-art manufacturing facilities in India.

Rajendra Velagapudi, Senior Vice President and CEO, Cyient DLM, commented, "We are proud to support the vision of an Atmanirbhar Bharat (self-reliant India) in the healthcare sector. It is a matter of immense pride that with Agappe’s new hematology product, even rural India and other remote locations of the country will have access to the best of diagnostic capabilities."

Cyient’s world-class facilities, project management, sourcing, supply chain management, production processes, buoyed by investments in the latest technologies as well as expertise in the delivery of quality products, make it a preferred manufacturing partner for aerospace, defense, medical, and industrial customers globally.

Dr. Satheesh Kumar CS, Senior Vice President, Agappe, said, "This partnership will enable Agappe to deliver high-quality, affordable, 100% made-in-India products by taking advantage of Cyient’s ultra-modern manufacturing facilities to manufacture some of the key components of Mispa Count X so as to reduce time-to-market and lower operating costs. We are eager to get started with full-scale production in our manufacturing facility at Cochin and fulfill customer orders on time."

About Cyient:
Cyient (Estd: 1991, NSE: CYIENT) is a global engineering and digital technology solutions company. As a Design, Build, and Maintain partner for leading organizations worldwide, Cyient takes solution ownership across the value chain to help customers focus on their core, innovate, and stay ahead of the curve. The company leverages digital technologies, advanced analytics capabilities, domain knowledge, and technical expertise to solve complex business problems.

Cyient partners with customers to operate as part of their extended team in ways that best suit their organization’s culture and requirements. Cyient’s industry focus includes aerospace and defense, healthcare, telecommunications, rail transportation, semiconductor, geospatial, industrial, and energy.

For more information, please visit www.cyient.com

Follow news about the company at @Cyient

Contact Details
Perfect Relations
Vishal Thapa
Mobile: +91 9701834446
Email: vthapa@perfectrelations.com

Logo – https://techent.tv/wp-content/uploads/2020/09/cyient-enters-into-a-manufacturing-collaboration-with-agappe-to-bring-world-class-diagnostic-capabilities-to-rural-india.jpg

Related Links :

http://www.cyient.com